Who makes A-101 32.5%?

A-101 32.5% is developed by Aclaris Therapeutics, Inc..

What are the side effects of A-101 32.5%?

Common side effects include Seasonal allergy, Erythema, Crusting, Arthritis, Induration, Hypopigmentation.

Last reviewed 2026-04-20 · How we verify

A-101 32.5%

Aclaris Therapeutics, Inc. · Phase 1 active Small molecule Quality 15/100

At a glance

Generic name	A-101 32.5%
Sponsor	Aclaris Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Seasonal allergy
Erythema
Crusting
Arthritis
Induration
Hypopigmentation
Hyperpigmentation
Abdominal Pain Upper
Diarrhoea
Toothache
Wound
Spinal column stenosis

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

A-101 32.5% CI brief — competitive landscape report
A-101 32.5% updates RSS · CI watch RSS
Aclaris Therapeutics, Inc. portfolio CI